MY162146A - Pharmaceutical composition - Google Patents
Pharmaceutical compositionInfo
- Publication number
- MY162146A MY162146A MYPI2013700146A MYPI2013700146A MY162146A MY 162146 A MY162146 A MY 162146A MY PI2013700146 A MYPI2013700146 A MY PI2013700146A MY PI2013700146 A MYPI2013700146 A MY PI2013700146A MY 162146 A MY162146 A MY 162146A
- Authority
- MY
- Malaysia
- Prior art keywords
- pharmaceutical composition
- subjects
- formula
- treatment
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38478110P | 2010-09-21 | 2010-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY162146A true MY162146A (en) | 2017-05-31 |
Family
ID=44674894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2013700146A MY162146A (en) | 2010-09-21 | 2011-09-12 | Pharmaceutical composition |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8686018B2 (OSRAM) |
| EP (2) | EP2619182B1 (OSRAM) |
| JP (1) | JP5956448B2 (OSRAM) |
| KR (1) | KR101911105B1 (OSRAM) |
| CN (1) | CN103097358B (OSRAM) |
| AU (1) | AU2011305872B2 (OSRAM) |
| BR (1) | BR112013002484B1 (OSRAM) |
| CA (1) | CA2806121C (OSRAM) |
| CL (1) | CL2013000675A1 (OSRAM) |
| CY (1) | CY1118680T1 (OSRAM) |
| DK (1) | DK2619182T3 (OSRAM) |
| ES (1) | ES2610185T3 (OSRAM) |
| HR (1) | HRP20170042T1 (OSRAM) |
| HU (1) | HUE031408T2 (OSRAM) |
| IL (1) | IL224288A (OSRAM) |
| LT (1) | LT2619182T (OSRAM) |
| ME (1) | ME02575B (OSRAM) |
| MX (1) | MX2013003162A (OSRAM) |
| MY (1) | MY162146A (OSRAM) |
| NZ (1) | NZ606629A (OSRAM) |
| PE (1) | PE20131343A1 (OSRAM) |
| PH (1) | PH12013500467A1 (OSRAM) |
| PL (1) | PL2619182T3 (OSRAM) |
| PT (1) | PT2619182T (OSRAM) |
| RS (1) | RS55566B1 (OSRAM) |
| RU (1) | RU2606510C2 (OSRAM) |
| SG (1) | SG188188A1 (OSRAM) |
| SI (1) | SI2619182T1 (OSRAM) |
| SM (2) | SMT201700008T1 (OSRAM) |
| UA (1) | UA113499C2 (OSRAM) |
| WO (1) | WO2012039972A1 (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3296B1 (ar) * | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
| LT3009426T (lt) | 2013-06-12 | 2018-07-25 | Kaken Pharmaceutical Co., Ltd. | 4-alkinilimidazolo darinys ir jį, kaip veiklųjį ingredientą, apimantis vaistas |
| TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
| WO2015179615A1 (en) * | 2014-05-23 | 2015-11-26 | Eisai R&D Management Co., Ltd | Combination therapies for the treatment of cancer |
| UY36680A (es) | 2015-05-19 | 2016-12-30 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas como inhibidores de quinasa |
| CN108368127B (zh) | 2015-07-23 | 2020-12-11 | 武田药品工业株式会社 | 化合物及其作为ep4受体拮抗剂的用途 |
| CN108473497B (zh) | 2015-10-16 | 2021-09-10 | 卫材R&D 管理有限公司 | Ep4拮抗剂 |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| CA3063632A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
| KR102626982B1 (ko) | 2017-05-18 | 2024-01-18 | 이도르시아 파마슈티컬스 리미티드 | Pge2 수용체 조절제로서의 피리미딘 유도체 |
| ES2896476T3 (es) | 2017-05-18 | 2022-02-24 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina |
| WO2018210994A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as pge2 receptor modulators |
| PE20191787A1 (es) | 2017-05-18 | 2019-12-24 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos |
| CN108929281B (zh) * | 2017-05-27 | 2021-12-24 | 华东师范大学 | 三氮唑类化合物及其合成方法和应用 |
| AU2019214193B2 (en) * | 2018-02-05 | 2022-06-16 | Foshan Ionova Biotherapeutics Co., Inc. | Heterobicyclic carboxylic acids for treating cancer or inflammatory diseases |
| US20230125494A1 (en) * | 2020-03-04 | 2023-04-27 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Synthesis of novel ep4 antagonist and use in cancer and inflammation |
| WO2022037601A1 (zh) * | 2020-08-18 | 2022-02-24 | 武汉人福创新药物研发中心有限公司 | 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在制备治疗癌症和炎症药物中的用途 |
| EP4245301A4 (en) | 2020-11-13 | 2024-08-21 | ONO Pharmaceutical Co., Ltd. | TREATMENT OF CANCER BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR |
| TWI877433B (zh) | 2020-11-30 | 2025-03-21 | 大陸商杭州阿諾生物醫藥科技有限公司 | 用於治療ｐｉｋ３ｃａ突變癌症的組合療法 |
| WO2022161418A1 (zh) * | 2021-01-28 | 2022-08-04 | 深圳晶泰科技有限公司 | 吡唑酰胺衍生物及其制备方法和应用 |
| US20240368088A1 (en) * | 2021-09-03 | 2024-11-07 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Ep4 antagonist compound as well as salt, polymorph and use thereof |
| CN115364222A (zh) * | 2021-09-09 | 2022-11-22 | 首都医科大学附属北京地坛医院 | Ep4受体抑制剂治疗肝纤维化的应用 |
| EP4452949A1 (en) | 2021-12-23 | 2024-10-30 | Eisai R&D Management Co., Ltd. | Crystalline salt form of ep4 antagonist |
| US20250381143A1 (en) * | 2021-12-30 | 2025-12-18 | Adlai Nortye Biopharma Co., Ltd. | A solid pharmaceutical composition |
| WO2024027599A1 (zh) * | 2022-08-04 | 2024-02-08 | 杭州阿诺生物医药科技有限公司 | 预测直肠癌对an0025联合放疗/放化疗(rt/crt)治疗敏感性的生物标志物 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0421671A (ja) * | 1990-05-16 | 1992-01-24 | Mitsubishi Kasei Corp | ４―ピラゾールカルボキサミド類およびこれを有効成分とする殺虫、殺ダニ剤 |
| IL104311A (en) * | 1992-02-05 | 1997-07-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
| US6211197B1 (en) * | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
| US7119108B1 (en) | 1999-10-18 | 2006-10-10 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| US7393842B2 (en) | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| TW591020B (en) | 2001-06-20 | 2004-06-11 | Wyeth Corp | 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
| US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| WO2004037212A2 (en) | 2002-10-24 | 2004-05-06 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
| FR2847160A1 (fr) | 2002-11-20 | 2004-05-21 | Oreal | Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| PT1641764E (pt) * | 2003-06-26 | 2011-10-27 | Novartis Ag | Inibidores de p38 quinase a base de heterociclo de 5 elementos |
| AU2004268839A1 (en) * | 2003-09-03 | 2005-03-10 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists |
| WO2005070889A1 (en) | 2004-01-23 | 2005-08-04 | E.I. Dupont De Nemours And Company | Herbicidal amides |
| KR20070006891A (ko) | 2004-05-04 | 2007-01-11 | 화이자 인코포레이티드 | 치환된 메틸 아릴 또는 헤테로아릴 아미드 화합물 |
| ES2327760T3 (es) * | 2004-05-04 | 2009-11-03 | Raqualia Pharma Inc | Compuestos de aril-heteroaril-amida ortosustituidos. |
| TW200716576A (en) | 2005-06-07 | 2007-05-01 | Shionogi & Co | Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| JP2008545776A (ja) * | 2005-06-11 | 2008-12-18 | ヴァーナリス アールアンドディー リミテッド | 癌および自己免疫疾患の治療における使用のためのピラゾール−置換ベンズイミダゾール誘導体 |
| CN101273013B (zh) * | 2005-09-27 | 2013-06-12 | 盐野义制药株式会社 | 具有pgd2受体拮抗活性的磺酰胺衍生物 |
| AU2006316087B2 (en) | 2005-11-21 | 2011-03-10 | Shionogi & Co., Ltd. | Heterocyclic compound having inhibitory activity on 11-beta-hydroxysteroid dehydrogenase type I |
| CN101415687B (zh) * | 2006-02-06 | 2012-02-08 | 大正制药株式会社 | 鞘氨醇-1-磷酸结合抑制物质 |
| EP2035376B1 (en) | 2006-06-12 | 2014-08-27 | Merck Canada Inc. | Indoline amide derivatives as ep4 receptor ligands |
| JP5259592B2 (ja) | 2006-08-11 | 2013-08-07 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体 |
| EA015931B1 (ru) | 2006-12-15 | 2011-12-30 | Глэксо Груп Лимитед | Бензамидные производные как агонисты ер-рецепторов |
| JP5301469B2 (ja) | 2007-02-26 | 2013-09-25 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体 |
| US7560936B1 (en) | 2007-04-24 | 2009-07-14 | Integrated Device Technology, Inc. | Method and apparatus for ground bounce and power supply bounce detection |
| AU2008263883B2 (en) | 2007-06-15 | 2014-03-13 | Basf Se | Method for producing difluoromethyl-substituted pyrazole compounds |
| EP2172447A4 (en) | 2007-07-03 | 2011-08-24 | Astellas Pharma Inc | amide |
| US20100292236A1 (en) * | 2007-07-19 | 2010-11-18 | H. Lundbeck A/S | 5-Membered Heterocyclic Amides And Related Compounds |
| CL2008002241A1 (es) | 2007-07-31 | 2009-12-28 | Bayer Cropscience Sa | Compuestos derivados de (hetero)aril-metilen-n-cicloalquil carboxamida condensados de 6 elementos con n-sustituido; composicion funguicida que comprende uno de dichos compuestos; y metodo para el control hongos fitopatogenos de cultivos agricolas. |
| GB0721611D0 (en) | 2007-11-02 | 2007-12-12 | Glaxo Group Ltd | Novel compounds |
| JP5411927B2 (ja) * | 2008-05-06 | 2014-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ１アンタゴニストとしてのピラゾール化合物 |
| DK2565191T3 (da) * | 2008-05-14 | 2014-11-10 | Astellas Pharma Inc | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexancarboxylsyrederivater som EP4-receptorantagonister der er anvendelige til behandlingen af kronisk nyresvigt eller diabetisk nephropati |
| US8680127B2 (en) | 2008-08-01 | 2014-03-25 | Bayer Intellectual Property Gmbh | Fungicide N-cycloalkyl-N-biphenylmethyl-carboxamide derivatives |
| JP5536773B2 (ja) * | 2008-08-14 | 2014-07-02 | ベータ・ファーマ・カナダ・インコーポレイテッド | Ｅｐ４受容体アンタゴニストとしてのヘテロ環式アミド誘導体 |
| MX2011003166A (es) | 2008-09-25 | 2011-04-27 | Merck Frosst Canada Ltd | Derivados de sulfonilurea beta-carbolina como antagonistas del receptor ep4. |
-
2011
- 2011-09-12 JP JP2013530177A patent/JP5956448B2/ja active Active
- 2011-09-12 EP EP11760631.9A patent/EP2619182B1/en active Active
- 2011-09-12 SM SM20170008T patent/SMT201700008T1/it unknown
- 2011-09-12 HU HUE11760631A patent/HUE031408T2/en unknown
- 2011-09-12 NZ NZ60662911A patent/NZ606629A/en unknown
- 2011-09-12 BR BR112013002484-4A patent/BR112013002484B1/pt active IP Right Grant
- 2011-09-12 PL PL11760631T patent/PL2619182T3/pl unknown
- 2011-09-12 EP EP16161460.7A patent/EP3061751A1/en not_active Withdrawn
- 2011-09-12 PH PH1/2013/500467A patent/PH12013500467A1/en unknown
- 2011-09-12 MX MX2013003162A patent/MX2013003162A/es active IP Right Grant
- 2011-09-12 CN CN201180045222.XA patent/CN103097358B/zh active Active
- 2011-09-12 AU AU2011305872A patent/AU2011305872B2/en active Active
- 2011-09-12 DK DK11760631.9T patent/DK2619182T3/en active
- 2011-09-12 PT PT117606319T patent/PT2619182T/pt unknown
- 2011-09-12 WO PCT/US2011/051163 patent/WO2012039972A1/en not_active Ceased
- 2011-09-12 ME MEP-2017-3A patent/ME02575B/me unknown
- 2011-09-12 SI SI201131067A patent/SI2619182T1/sl unknown
- 2011-09-12 LT LTEP11760631.9T patent/LT2619182T/lt unknown
- 2011-09-12 RU RU2013118209A patent/RU2606510C2/ru active
- 2011-09-12 HR HRP20170042TT patent/HRP20170042T1/hr unknown
- 2011-09-12 KR KR1020137004494A patent/KR101911105B1/ko active Active
- 2011-09-12 ES ES11760631.9T patent/ES2610185T3/es active Active
- 2011-09-12 SG SG2013007174A patent/SG188188A1/en unknown
- 2011-09-12 PE PE2013000320A patent/PE20131343A1/es active IP Right Grant
- 2011-09-12 MY MYPI2013700146A patent/MY162146A/en unknown
- 2011-09-12 CA CA2806121A patent/CA2806121C/en active Active
- 2011-09-12 RS RS20170008A patent/RS55566B1/sr unknown
- 2011-09-12 UA UAA201304961A patent/UA113499C2/uk unknown
-
2013
- 2013-01-17 IL IL224288A patent/IL224288A/en active IP Right Grant
- 2013-03-12 US US13/795,768 patent/US8686018B2/en active Active
- 2013-03-12 CL CL2013000675A patent/CL2013000675A1/es unknown
-
2014
- 2014-02-05 US US14/173,170 patent/US9000024B2/en active Active
-
2017
- 2017-01-09 SM SM201700008T patent/SMT201700008B/it unknown
- 2017-01-19 CY CY20171100079T patent/CY1118680T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013500467A1 (en) | Pharmaceutical composition | |
| MX344530B (es) | Compuestos de benceno substituido. | |
| PH12015500825A1 (en) | Substituted benzene compounds | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| PH12015501609A1 (en) | Phenicol antibacterials | |
| IN2015DN01156A (OSRAM) | ||
| UA110612C2 (uk) | Похідні 1-аміно-2-циклопропілетилборонової кислоти | |
| MY153915A (en) | Organic compounds | |
| PH12015501385A1 (en) | Autotaxin inhibitors | |
| MY166171A (en) | Aryl- or heteroaryl-substituted benzene compounds | |
| MA33803B1 (fr) | Inhibiteur de bromodomaine de benzodiazépine | |
| EA201491617A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| UA109010C2 (en) | Morpholino pyrividines and their use in therapy | |
| EA201370018A1 (ru) | Составы рифаксимина и их применение | |
| MX2013004061A (es) | Analogos de ciclosporina. | |
| MX342947B (es) | Tratamiento de diabetes tipo 2. | |
| SG158091A1 (en) | Imidazoazepinone compounds | |
| IN2015DN02109A (OSRAM) | ||
| EP2563785A4 (en) | Compounds as Agonists Against S1P1 Receptors | |
| MX2014004742A (es) | Nuevos agentes antibacterianos de fenicol. | |
| MX2013002446A (es) | Derivados de tetrahidropirrolopirazina sustituidos. | |
| TN2010000583A1 (en) | Organic compounds |